BioCentury | Apr 12, 2019
Company News

International partners to develop immune stimulants for neurology

...Brigham and Women's Hospital, immunology company I-Mab Biopharma, neurology company Jiangsu NHWA and CDMO Biodextris partnered to...
...development; Biodextris (Montreal, Quebec) will be responsible for CMC development and manufacturing; and I-Mab and Jiangsu NHWA Pharmaceutical Co. Ltd....
...at least one program in early 2020, Tang said. Allison Johnson, Staff Writer Brigham and Women's Hospital I-Mab Biopharma Jiangsu NHWA Pharmaceutical Co. Ltd. Biodextris Weimin...
BioCentury | Jun 30, 2014
Clinical News

DP-VPA regulatory update

...D-Pharm said partner Jiangsu NHWA received notice that China Food and Drug Administration (CFDA) granted Fast Track...
...and Drug Administration (CFDA) granted Fast Track designation to DP-VPA to treat epilepsy. D-Pharm said Jiangsu NHWA...
...a Phase I trial in China with the product, but did not provide a timeline. Jiangsu NHWA...
BioCentury | May 7, 2012
Company News

D-Pharm, Jiangsu NHWA deal

...D-Pharm received a $1 million milestone payment from Jiangsu NHWA under a 2011 deal that granted Jiangsu NHWA...
...trial in epilepsy patients (see BioCentury, June 6, 2011). D-Pharm Ltd. (Tel Aviv:DPRM), Rehovot, Israel Jiangsu NHWA Pharmaceutical Co. Ltd....
BioCentury | Jun 6, 2011
Company News

D-Pharm, Jiangsu NHWA deal

...for the end of 2012. Terms were not disclosed. D-Pharm Ltd. (Tel Aviv:DPRM), Rehovot, Israel Jiangsu NHWA Pharmaceutical Co. Ltd....
Items per page:
1 - 4 of 4
BioCentury | Apr 12, 2019
Company News

International partners to develop immune stimulants for neurology

...Brigham and Women's Hospital, immunology company I-Mab Biopharma, neurology company Jiangsu NHWA and CDMO Biodextris partnered to...
...development; Biodextris (Montreal, Quebec) will be responsible for CMC development and manufacturing; and I-Mab and Jiangsu NHWA Pharmaceutical Co. Ltd....
...at least one program in early 2020, Tang said. Allison Johnson, Staff Writer Brigham and Women's Hospital I-Mab Biopharma Jiangsu NHWA Pharmaceutical Co. Ltd. Biodextris Weimin...
BioCentury | Jun 30, 2014
Clinical News

DP-VPA regulatory update

...D-Pharm said partner Jiangsu NHWA received notice that China Food and Drug Administration (CFDA) granted Fast Track...
...and Drug Administration (CFDA) granted Fast Track designation to DP-VPA to treat epilepsy. D-Pharm said Jiangsu NHWA...
...a Phase I trial in China with the product, but did not provide a timeline. Jiangsu NHWA...
BioCentury | May 7, 2012
Company News

D-Pharm, Jiangsu NHWA deal

...D-Pharm received a $1 million milestone payment from Jiangsu NHWA under a 2011 deal that granted Jiangsu NHWA...
...trial in epilepsy patients (see BioCentury, June 6, 2011). D-Pharm Ltd. (Tel Aviv:DPRM), Rehovot, Israel Jiangsu NHWA Pharmaceutical Co. Ltd....
BioCentury | Jun 6, 2011
Company News

D-Pharm, Jiangsu NHWA deal

...for the end of 2012. Terms were not disclosed. D-Pharm Ltd. (Tel Aviv:DPRM), Rehovot, Israel Jiangsu NHWA Pharmaceutical Co. Ltd....
Items per page:
1 - 4 of 4